Theravance Biopharma Posts $61m Q4 Profit, EPS Miss Triggers 60% Cost-Cut Plan
TBPH reported Q4 profit of $61m (EPS $1.15) while adjusted EPS of $0.06 missed the $0.44 consensus and revenue of $45.9m trailed $59.8m forecasts. The firm plans to cut costs 60% for $60–70m annualized savings and accelerated a strategic review of value-maximizing options.
1. Q4 and Full-Year Financial Results
Theravance Biopharma reported Q4 profit of $61 million, or $1.15 per share, while non-GAAP adjusted EPS of $0.06 fell short of the $0.44 consensus. Q4 revenue was $45.9 million versus $59.8 million expected, and full-year 2025 revenue reached $107.5 million with net profit of $105.9 million.
2. Commercial Performance and Milestones
YUPELRI net sales recognized by Viatris grew 12% year-over-year to $266.6 million in 2025, triggering a $25 million sales-based milestone payment. TRELEGY global net sales of $3.9 billion in 2025 generated a $50 million milestone from Royalty Pharma, and YUPELRI Q4 net sales of $70.6 million rose 6% year-on-year.
3. Strategic Review and Cost Reduction Plan
In response to the Phase 3 ampreloxetine study result, the company is implementing a restructuring to reduce operating expenses by approximately 60%, targeting $60–70 million of annualized cash flow by Q3 2026. The independent Strategic Review Committee has accelerated evaluation of value-maximizing alternatives, including potential sale options.